Loading...
An Update on the Current State of SARS-CoV-2 Mac1 Inhibitors
O'Connor, Joseph J. Ferraris, Dana Fehr, Anthony R.
O'Connor, Joseph J.
Ferraris, Dana
Fehr, Anthony R.
Citations
Altmetric:
Abstract
Non-structural protein 3 (nsp3) from all coronaviruses (CoVs) contains a conserved macrodomain, known as Mac1, that has been proposed as a potential therapeutic target for CoVs due to its critical role in viral pathogenesis. Mac1 is an ADP-ribose binding protein and ADP-ribosylhydrolase that promotes replication and blocks IFN responses, though the precise mechanisms it uses to carry out these functions remain unknown. Over the past 3 years following the onset of COVID-19, several groups have used high-throughput screening with multiple assays and chemical modifications to create unique chemical inhibitors of the SARS-CoV-2 Mac1 protein. Here, we summarize the current efforts to identify selective and potent inhibitors of SARS-CoV-2 Mac1.
Description
Date
2023-10-07
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI
Collections
Research Projects
Organizational Units
Journal Issue
Keywords
Coronavirus, SARS-CoV-2, Macrodomain, Mac1, ADP-ribosylation, Inhibitors, ADP-ribosylhydrolase
Citation
O'Connor JJ, Ferraris D, Fehr AR. An Update on the Current State of SARS-CoV-2 Mac1 Inhibitors. Pathogens. 2023 Oct 7;12(10):1221. doi: 10.3390/pathogens12101221. PMID: 37887737; PMCID: PMC10610136